Therapeutic vaccination to block receptor-ligand interactions.
Expert Opin Biol Ther
; 3(3): 469-76, 2003 Jun.
Article
em En
| MEDLINE
| ID: mdl-12783615
ABSTRACT
Many chronic diseases are caused by non-physiological interactions of certain ligands with their receptors. Conventional treatment of these diseases with synthetic drugs or monoclonal antibodies (mAbs) is efficient, but problematic due to the non-compliance of patients and the risk of adverse side effects. Novel therapeutic approaches are focusing on strategies of active immunisation aimed at the induction of a humoral immune response directed against the deleterious receptor-ligand interaction. Autoantibody production has been achieved by several vaccine formulations, including conjugates of self-antigens to foreign T helper (Th) cell epitopes, virus-like particles coated with self-antigens, and naked DNA vectors. All of these approaches have the potential to be developed for clinical use if important safety issues, related to the possible long-term presence of self-reactive antibodies in the serum of vaccinated individuals and the risk of undesired T cell responses, can be properly addressed.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Citocinas
/
Receptores de Citocinas
/
Anticorpos Bloqueadores
/
Vacinas de DNA
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Opin Biol Ther
Ano de publicação:
2003
Tipo de documento:
Article